This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Corrigendum to "Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study" [Lung Cancer 85 (2014) 415–419]. Issue 2 (February 2015)
Record Type:
Journal Article
Title:
Corrigendum to "Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study" [Lung Cancer 85 (2014) 415–419]. Issue 2 (February 2015)
Main Title:
Corrigendum to "Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study" [Lung Cancer 85 (2014) 415–419]